Status:
COMPLETED
Stalevo in Early Wearing-Off Patients
Lead Sponsor:
Orion Corporation, Orion Pharma
Conditions:
Idiopathic Parkinson's Disease
Eligibility:
All Genders
30+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to demonstrate in patients with Parkinson's disease that, when compared to levodopa/carbidopa, Stalevo will delay the time from initiation of study drug to the time an inc...
Eligibility Criteria
Inclusion
- Idiopathic Parkinson's disease
- Treatment with 3 equal daily doses of levodopa/carbidopa up to 450 mg/day
- Unchanged antiparkinsonian medication for 6 weeks prior to baseline
Exclusion
- Secondary or atypical parkinsonism
- Patients with daily unpredictable OFF periods or painful dyskinesia
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
223 Patients enrolled
Trial Details
Trial ID
NCT00125567
Start Date
August 1 2005
End Date
March 1 2009
Last Update
June 22 2009
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Aalborg Hospital
Aalborg, Denmark, DK-9000 Aalborg
2
Bispebjerg Hospital
Copenhagen, Denmark
3
Århus Kommunehospital
Nørrebrogade 44, Denmark, 8000
4
South Karelia Central Hospital
Lappeenranta, Finland